BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology 2020;159:139-47. [PMID: 32224129 DOI: 10.1053/j.gastro.2020.03.039] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Oh K, Oh EH, Noh SM, Park SH, Kim N, Hwang SW, Park SH, Yang D, Byeon J, Myung S, Yang S, Ye BD. Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy. Clin Transl Gastroenterol 2022;Publish Ahead of Print. [DOI: 10.14309/ctg.0000000000000442] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2021;54:1298-308. [PMID: 34559428 DOI: 10.1111/apt.16605] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
3 Han ZM, Chen BX, Zhou Q, Liu HB, Xu PC, Zhi FC. Predictors of infliximab-induced deep remission in treatment-naïve patients with isolated small bowel Crohn's disease. Scand J Gastroenterol 2021;56:1422-6. [PMID: 34461786 DOI: 10.1080/00365521.2021.1971759] [Reference Citation Analysis]
4 Magro F, Sottomayor C, Alves C, Santiago M, Ministro P, Lago P, Correia L, Gonçalves R, Carvalho D, Portela F, Dias CC, Dignass A, Danese S, Peyrin-biroulet L, Estevinho MM, Leão Moreira P. Composite outcomes in observational studies of Crohn’s disease: a systematic review and meta-analysis. Therap Adv Gastroenterol 2022;15:175628482210927. [DOI: 10.1177/17562848221092754] [Reference Citation Analysis]
5 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS. Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease. J Crohns Colitis 2021:jjab183. [PMID: 34664635 DOI: 10.1093/ecco-jcc/jjab183] [Reference Citation Analysis]
7 Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov 2021;2:100070. [PMID: 34988431 DOI: 10.1016/j.crphar.2021.100070] [Reference Citation Analysis]
8 Noor NM, Lee JC. The Endoscopic Healing Index in Crohn's Disease: A Serum Proteomic Biomarker for Monitoring Disease Activity. Inflamm Bowel Dis 2022:izac126. [PMID: 35704706 DOI: 10.1093/ibd/izac126] [Reference Citation Analysis]
9 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Reference Citation Analysis]
10 Kutschera M, Waldhör T, Gröchenig HP, Haas T, Wenzl H, Steiner P, Koch R, Feichtenschlager T, Eckhardt G, Mayer A, Kirchgatterer A, Ludwiczek O, Platzer R, Papay P, Gartner J, Fuchssteiner H, Peters PG, Reicht G, Moser G, Dejaco C, Vogelsang H, Primas C, Novacek G, Miehsler W; Austrian IBD Study Group. Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease. United European Gastroenterol J 2021;9:72-81. [PMID: 32723070 DOI: 10.1177/2050640620946874] [Reference Citation Analysis]
11 Macaluso FS, Maida M, Grova M, Crispino F, Teresi G, Orlando A, Orlando A. Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Therap Adv Gastroenterol 2021;14:17562848211010668. [PMID: 33995582 DOI: 10.1177/17562848211010668] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570-83. [PMID: 33359090 DOI: 10.1053/j.gastro.2020.12.031] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 51.0] [Reference Citation Analysis]
13 Khoudari G, Mansoor E, Click B, Alkhayyat M, Saleh MA, Sinh P, Katz J, Cooper GS, Regueiro M. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study. Clinical Gastroenterology and Hepatology 2020. [DOI: 10.1016/j.cgh.2020.10.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
14 Liu F, Tang J, Ye L, Tan J, Qiu Y, Hu F, He J, Chen B, He Y, Zeng Z, Mao R, Cao Q, Gao X, Chen M. Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study. Clin Transl Gastroenterol 2022;13:e00493. [PMID: 35758823 DOI: 10.14309/ctg.0000000000000493] [Reference Citation Analysis]
15 Candia R, Bravo-Soto GA, Monrroy H, Hernandez C, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2020;8:CD012328. [PMID: 32746500 DOI: 10.1002/14651858.CD012328.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones G, Lees CW. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:1835-1844.e6. [DOI: 10.1016/j.cgh.2020.08.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
17 Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC; Scientific Workshop Steering Committee . Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. J Crohns Colitis 2021;15:1431-42. [PMID: 33730756 DOI: 10.1093/ecco-jcc/jjab050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Ungaro RC, Hu L, Ji J, Nayar S, Kugathasan S, Denson LA, Hyams J, Dubinsky MC, Sands BE, Cho JH. Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease. Aliment Pharmacol Ther 2021;53:281-90. [PMID: 33131065 DOI: 10.1111/apt.16136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Yoon H, Jangi S, Dulai PS, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. Inflamm Bowel Dis 2021;27:1277-84. [PMID: 33236763 DOI: 10.1093/ibd/izaa301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022;162:1525-42. [PMID: 34995532 DOI: 10.1053/j.gastro.2021.09.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Rodríguez-Lago I, Zabana Y, Barreiro-de Acosta M. Diagnosis and natural history of preclinical and early inflammatory bowel disease. Ann Gastroenterol 2020;33:443-52. [PMID: 32879589 DOI: 10.20524/aog.2020.0508] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Al Khoury A, Xiao Y, Golovics PA, Kohen R, Afif W, Wild G, Friedman G, Galiatsatos P, Hilzenrat N, Szilagyi A, Wyse J, Cohen A, Bitton A, Bessissow T, Lakatos PL. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. Dig Liver Dis 2021;53:980-6. [PMID: 33640302 DOI: 10.1016/j.dld.2021.02.006] [Reference Citation Analysis]
23 Moses J, Sandberg K, Winberry G, Riera D, DeLozier S, Gupta SK, Reilly N, Park KT, Picoraro J. Clinical Practice Survey of Repeat Endoscopy in Pediatric Inflammatory Bowel Disease in North America. J Pediatr Gastroenterol Nutr 2021;73:61-6. [PMID: 33633082 DOI: 10.1097/MPG.0000000000003100] [Reference Citation Analysis]
24 Spencer EA, Dubinsky MC. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am 2021;68:1171-90. [PMID: 34736583 DOI: 10.1016/j.pcl.2021.07.011] [Reference Citation Analysis]
25 Schmidt C, Bachmann O, Baumgart DC, Goetz M, Drvarov O, Kucharzik TF, Kühbacher T, Langhorst J, Maul J, Mohl W, Mudter J, Repp M, Sturm A, Witzemann D, Atreya R. [Position paper on endoscopic reporting in IBD]. Z Gastroenterol 2021. [PMID: 34284522 DOI: 10.1055/a-1504-9782] [Reference Citation Analysis]
26 Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? J Clin Med 2020;9:E2646. [PMID: 32823997 DOI: 10.3390/jcm9082646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022:S0016-5085(21)04072-5. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
28 Honig G, Larkin PB, Heller C, Hurtado-Lorenzo A. Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S1-S16. [PMID: 34791292 DOI: 10.1093/ibd/izab230] [Reference Citation Analysis]
29 Dulai PS, Jairath V, Narula N, Wong E, Kochhar GS, Colombel JF, Sandborn WJ. A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. Am J Gastroenterol 2021;116:1709-19. [PMID: 34587127 DOI: 10.14309/ajg.0000000000001263] [Reference Citation Analysis]
30 Noor NM, Hart AL, Irving PM, Ghosh S, Parkes M, Raine T. Clinical trials (and tribulations): the immediate effects of COVID-19 on IBD clinical research activity in the United Kingdom. J Crohns Colitis 2020:jjaa137. [PMID: 32598438 DOI: 10.1093/ecco-jcc/jjaa137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
31 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Torres J, Ungaro RC, Colombel JF. Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We? Gastroenterology 2022;162:1452-5. [PMID: 34995527 DOI: 10.1053/j.gastro.2021.07.051] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Torres J, Declerck P. Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoring. Curr Opin Pharmacol 2020;55:iii-vi. [PMID: 33357460 DOI: 10.1016/j.coph.2020.12.004] [Reference Citation Analysis]
34 Mitselos IV, Fousekis FS, Lamouri C, Katsanos KH, Christodoulou DK. Current noninvasive modalities in Crohn's disease monitoring. Ann Gastroenterol 2021;34:770-80. [PMID: 34815642 DOI: 10.20524/aog.2021.0648] [Reference Citation Analysis]
35 Yang JY, Lund JL, Pate V, Kappelman MD. Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019. Inflamm Bowel Dis 2022:izac136. [PMID: 35929644 DOI: 10.1093/ibd/izac136] [Reference Citation Analysis]
36 Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01268-4. [PMID: 34843987 DOI: 10.1016/j.cgh.2021.11.030] [Reference Citation Analysis]
37 Kennedy NA. Integrating a treat to target approach into clinical practice in 2020. J Gastroenterol Hepatol 2021;36 Suppl 1:6-7. [PMID: 33817849 DOI: 10.1111/jgh.15446] [Reference Citation Analysis]
38 Scaldaferri F, Ianiro G, Privitera G, Lopetuso LR, Vetrone LM, Petito V, Pugliese D, Neri M, Cammarota G, Ringel Y, Costamagna G, Gasbarrini A, Boskoski I, Armuzzi A. The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflamm Bowel Dis. 2020;26:1306-1314. [PMID: 32720978 DOI: 10.1093/ibd/izaa181] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
39 Zilbauer M, Heuschkel R. Disease Prognostic Biomarkers in Inflammatory Bowel Diseases—A Reality Check. Journal of Crohn's and Colitis 2021. [DOI: 10.1093/ecco-jcc/jjab118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Limdi JK. Editorial commentary on the Indian Journal of Gastroenterology May-June 2020. Indian J Gastroenterol 2020;39:211-3. [PMID: 32710225 DOI: 10.1007/s12664-020-01077-0] [Reference Citation Analysis]
41 Porter AC, Aubrecht J, Birch C, Braun J, Cuff C, Dasgupta S, Gale JD, Hinton R, Hoffmann SC, Honig G, Linggi B, Schito M, Casteele NV, Sauer JM. Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions. Inflamm Bowel Dis 2020;26:1498-508. [PMID: 32840322 DOI: 10.1093/ibd/izaa215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
42 Torres J, Riddle M, Colombel JF. Reply. Gastroenterology 2021;160:476-7. [PMID: 33159925 DOI: 10.1053/j.gastro.2020.10.045] [Reference Citation Analysis]
43 Plevris N, Lees CW. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology 2022:S0016-5085(22)00078-6. [PMID: 35101422 DOI: 10.1053/j.gastro.2022.01.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Rodríguez-Lago I, Barreiro-de Acosta M. Look at Both Sides of the Coin in Determining Risk of Complicated Crohn's Disease. Clin Gastroenterol Hepatol 2021;19:1503-4. [PMID: 33249022 DOI: 10.1016/j.cgh.2020.07.027] [Reference Citation Analysis]
45 Verburgt CM, Heutink WP, Kuilboer LIM, Dickmann JD, van Etten-Jamaludin FS, Benninga MA, de Jonge WJ, Van Limbergen JE, Tabbers MM. Antibiotics in pediatric inflammatory bowel diseases: a systematic review. Expert Rev Gastroenterol Hepatol 2021;15:891-908. [PMID: 34148466 DOI: 10.1080/17474124.2021.1940956] [Reference Citation Analysis]
46 Cassinotti A, Corona A, Duca P, Nebuloni M, Maconi G, Fociani P, Ardizzone S. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00642-X. [PMID: 34139332 DOI: 10.1016/j.cgh.2021.06.014] [Reference Citation Analysis]
47 Ankersen DV, Weimers P, Marker D, Teglgaard Peters-Lehm C, Bennedsen M, Rosager Hansen M, Olsen J, Elmegaard Madsen M, Burisch J, Munkholm P. Costs of electronic health vs. standard care management of inflammatory bowel disease across three years of follow-up-a Danish register-based study. Scand J Gastroenterol 2021;56:520-9. [PMID: 33645378 DOI: 10.1080/00365521.2021.1892176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Dal Buono A, Gabbiadini R, Furfaro F, Argollo M, Trigo TVT, Repici A, Roda G. Endoscopic Surveillance in Inflammatory Bowel Diseases: Selecting a Suitable Technology. Front Med 2022;9:855652. [DOI: 10.3389/fmed.2022.855652] [Reference Citation Analysis]
49 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2021:izab228. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Kwapisz L, Bruining DH, Fletcher JG. Using MR Enterography and CT Enterography for Routine Crohn's Surveillance: How We Do It Now, and How We Hope to Do it in the Future. Korean J Radiol 2022;23:1-5. [PMID: 34983088 DOI: 10.3348/kjr.2021.0846] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Dolinger M, Verstockt B. Ulcerative colitis, a transmural disease requiring an accurate IUS assessment in the current treat-to-target era. United European Gastroenterol J 2022. [PMID: 35230746 DOI: 10.1002/ueg2.12215] [Reference Citation Analysis]
52 Holmer AK, Boland BS, Singh S, Neill J, Le H, Miralles A, Collins AE, Sandborn WJ, Dulai PS. A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. Inflamm Bowel Dis 2022:izac117. [PMID: 35704691 DOI: 10.1093/ibd/izac117] [Reference Citation Analysis]
53 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Reference Citation Analysis]
54 Gergely M, Deepak P. Tools for the Diagnosis and Management of Crohn's Disease. Gastroenterol Clin North Am 2022;51:213-39. [PMID: 35595412 DOI: 10.1016/j.gtc.2021.12.003] [Reference Citation Analysis]
55 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
56 Nardone OM, Bazarova A, Bhandari P, Cannatelli R, Daperno M, Ferraz J, Goetz M, Gui X, Hayee B, De Hertogh G, Lazarev M, Li J, Parra-Blanco A, Pastorelli L, Panaccione R, Occhipinti V, Rath T, Smith SCL, Shivaji UN, Tontini GE, Vieth M, Villanacci V, Zardo D, Bisschops R, Kiesslich R, Ghosh S, Iacucci M. Endoscopic remission assessed with PICaSSO virtual electronic chromendoscopy accurately predicts clinical outcomes in ulcerative colitis. United European Gastroenterol J 2022. [PMID: 35194978 DOI: 10.1002/ueg2.12185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
57 Noor NM, Parkes M, Raine T. Moving towards more patient-centred clinical trials in IBD. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34312526 DOI: 10.1038/s41575-021-00500-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Mattoo VY, Basnayake C, Connell WR, Ding N, Kamm MA, Lust M, Niewiadomski O, Thompson A, Wright EK. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. Aliment Pharmacol Ther 2021;54:249-66. [PMID: 34153124 DOI: 10.1111/apt.16479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Yanai H, Goren I, Dotan I. Reply. Clin Gastroenterol Hepatol 2021;19:1504-5. [PMID: 33249028 DOI: 10.1016/j.cgh.2020.08.008] [Reference Citation Analysis]